



Published in final edited form as:

*Circ Res.* 2021 March 19; 128(6): 738–751. doi:10.1161/CIRCRESAHA.120.317715.

## Myocardial Blood Flow Control by Oxygen Sensing Vascular Kv $\beta$ Proteins

Vahagn Ohanyan<sup>2,\*</sup>, Sean M. Raph<sup>1,\*</sup>, Marc M. Dwenger<sup>1</sup>, Xuemei Hu<sup>1</sup>, Thomas Pucci<sup>2</sup>, Gregory Mack<sup>2</sup>, Joseph B. Moore IV<sup>1</sup>, William M. Chilian<sup>2</sup>, Aruni Bhatnagar<sup>1</sup>, Matthew A. Nystoriak<sup>1</sup>

<sup>1</sup>Department of Medicine, Division of Environmental Medicine, Diabetes and Obesity Center, University of Louisville, Louisville, KY

<sup>2</sup>Department of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown Ohio.

### Abstract

**Rationale:** Voltage-gated potassium (Kv) channels in vascular smooth muscle are essential for coupling myocardial blood flow (MBF) with the metabolic demand of the heart. These channels consist of a transmembrane pore domain that associates with auxiliary Kv $\beta$ 1 and Kv $\beta$ 2 proteins, which differentially regulate Kv function in excitable cells. Nonetheless, the physiological role of Kv $\beta$  proteins in regulating vascular tone and metabolic hyperemia in the heart remains unknown.

**Objective:** To test the hypothesis that Kv $\beta$  proteins confer oxygen sensitivity to vascular tone and are required for regulating blood flow in the heart.

**Methods and Results:** Mice lacking Kv $\beta$ 2 subunits exhibited suppressed MBF, impaired cardiac contractile performance, and failed to maintain elevated arterial blood pressure in response to catecholamine-induced stress. In contrast, ablation of Kv $\beta$ 1.1 reduced cardiac workload, modestly elevated MBF, and preserved cardiac function during stress compared with wild type mice. Coronary arteries isolated from Kv $\beta$ 2<sup>-/-</sup>, but not Kv $\beta$ 1.1<sup>-/-</sup>, mice, had severely blunted vasodilation to hypoxia when compared with arteries from wild type mice. Moreover, vasodilation of small diameter coronary and mesenteric arteries due to L-lactate, a biochemical marker of reduced tissue oxygenation and anaerobic metabolism, was significantly attenuated in vessels isolated from Kv $\beta$ 2<sup>-/-</sup> mice. Inducible enhancement of the Kv $\beta$ 1:Kv $\beta$ 2 ratio in Kv1 channels of arterial smooth muscle abolished L-lactate-induced vasodilation and suppressed the relationship between MBF and cardiac workload.

---

**Address Correspondence to:** Dr. Matthew A. Nystoriak, University of Louisville, Diabetes and Obesity Center, Delia Baxter Bldg., 580 S. Preston St., Rm 421B, Louisville, KY, 40202, matthew.nystoriak@louisville.edu, Dr. Vahagn Ohanyan, Northeast Ohio Medical University, Department of Integrative Medical Sciences, Rootstown, OH 44272, vohanyan@neomed.edu.

\* Authors contributed equally


### DISCLOSURES

None

**Publisher's Disclaimer:** This article is published in its accepted form. It has not been copyedited and has not appeared in an issue of the journal. Preparation for inclusion in an issue of *Circulation Research* involves copyediting, typesetting, proofreading, and author review, which may lead to differences between this accepted version of the manuscript and the final, published version.

**Conclusions:** The Kv $\beta$  proteins differentially regulate vascular tone and myocardial blood flow, whereby Kv $\beta$ 2 promotes and Kv $\beta$ 1.1 inhibits oxygen-dependent vasodilation and augments blood flow upon heightened metabolic demand.

### Graphical Abstract



### Keywords

Coronary Circulation; Ion Channels/Membrane Transport; Metabolism; Physiology; Vascular Biology; coronary arteries; myogenic tone; voltage-gated potassium channels; nicotinamide adenine dinucleotide; microcirculation; aldo-keto reductase; ion channels; ischemia

## INTRODUCTION

An imbalance between myocardial oxygen supply and demand is a salient feature of heart disease, which remains the leading cause of death worldwide.<sup>1</sup> Impaired cardiac function associated with inadequate myocardial perfusion is commonly observed in patients with heart failure, hypertension, diabetes, and coronary artery disease.<sup>2–5</sup> Even in the absence of stenoses in large diameter conduit arteries, suppressed vasodilator capacity of small diameter coronary arteries and arterioles can lead to ischemia.<sup>6, 7</sup> Despite the vital importance of oxygen delivery to the preservation of cardiac structure and function, the fundamental mechanisms by which the coronary vasculature responds to fluctuations in myocardial metabolic demand remain poorly understood.

In the healthy heart, the coronary arteries and arterioles remain partially constricted, and they dilate or constrict further according to myocardial requirements for oxygen and nutrient delivery.<sup>8, 9</sup> As myocardial oxygen consumption increases (e.g., due to an increase in heart rate, myocardial contractility, or afterload), there is a corresponding demand for an increase in oxygen supply to sustain oxidative energy production. However, with little reserve for increased oxygen extraction, sustained cardiac function relies on the intimate link between

local and regional metabolic activity and vasodilation of the coronary vascular bed to deliver adequate blood flow to the myocardium (i.e., metabolic hyperemia).<sup>10</sup> In searching for molecular entities that couple vascular function to myocardial oxygen demand, recent studies from our group<sup>11, 12</sup> and others<sup>13</sup> have found that increased cardiac work promotes coronary vasodilation and hyperemia via the activation of Kv1 channels in smooth muscle cells. Nonetheless, how vascular Kv1 channels sense changes in oxygen demand to regulate blood flow to the heart is unclear.

In this study, we tested the hypothesis that regulation of myocardial blood flow (MBF) by Kv1 channels depends upon their auxiliary Kv $\beta$  subunits. The Kv $\beta$  proteins are functional aldo-keto reductases that bind NAD(P)(H) and differentially regulate channel gating in response to changes in cellular redox status.<sup>14, 15</sup> Hence, these proteins represent a plausible molecular link between metabolic activity, oxygen availability, and Kv activity that could regulate vasoreactivity.<sup>16</sup> The mammalian genome encodes three Kv $\beta$  proteins, which have been shown to control the voltage sensitivity, surface localization, and subcellular distribution of Kv1 channels in excitable cells of the cardiovascular and nervous systems.<sup>17</sup> Consistent with this, in our previous work, we reported that Kv $\beta$  proteins support the functional expression of Kv channels in cardiomyocytes and contribute to the metabolic regulation of cardiac repolarization.<sup>18</sup> The Kv $\beta$  proteins are expressed throughout the coronary vasculature of humans<sup>19</sup> and rodents,<sup>20</sup> and we have recently reported that native Kv1 channels of coronary arterial myocytes are heteromeric assemblies of Kv $\beta$ 1.1 and Kv $\beta$ 2 proteins.<sup>20</sup> Using a combination of genetically engineered mice with *ex vivo* and *in vivo* approaches, we now report that Kv $\beta$ 1.1 and Kv $\beta$ 2 have contrasting roles in regulating MBF and cardiac function under stress, and that they impart oxygen sensitivity to vascular tone.

## METHODS

### Data Availability.

Materials used for this study and supporting data are available from the corresponding authors upon reasonable request. Please see the Major Resources Table in the Supplemental Materials. All animal procedures used for this study were conducted in accordance with the Institutional Animal Care and Use Committee at the University of Louisville and Northeast Ohio Medical University, per the guidelines set forth by the National Institutes of Health. An expanded Materials and Methods can be found in the Online Supplement.

## RESULTS

### Kv $\beta$ 2 is required for sustained cardiac pump function during stress.

Under conditions of heightened cardiac workload, sustained pump function is critically dependent on Kv1-mediated coronary vasodilation for sufficient oxygen delivery to meet myocardial metabolic demand.<sup>11, 12, 21</sup> We first tested whether loss of Kv $\beta$  proteins affects cardiac performance under stress. Figure 1A shows representative M mode echocardiographic images from wild type (WT) and Kv $\beta$ 2<sup>-/-</sup> animals during intravenous infusion of norepinephrine (5  $\mu$ g/kg·min<sup>-1</sup>). Norepinephrine enhanced cardiac function, as indicated by an increase in ejection fraction. However, steady-state ejection fraction during infusion of 2.5 and 5  $\mu$ g/kg·min<sup>-1</sup> norepinephrine was significantly lower in Kv $\beta$ 2<sup>-/-</sup>

animals than in WT animals (Figure 1A, B). Specifically, ejection fraction after ~1 min of  $5 \mu\text{g}/\text{kg}\cdot\text{min}^{-1}$  norepinephrine infusion was  $71 \pm 1.7\%$  in  $\text{Kv}\beta 2^{-/-}$  mice versus  $84 \pm 2.2\%$  in WT animals. Ejection fraction in  $\text{Kv}\beta 1.1^{-/-}$  mice did not differ significantly from that in WT mice at any dose of norepinephrine ( $P = 0.093$ ).

Figure 1C shows exemplary effects of norepinephrine infusion on arterial blood pressure in WT and  $\text{Kv}\beta 2^{-/-}$  mice. Norepinephrine infusion increased steady state blood pressure in both groups. Consistent with our previous report,<sup>12</sup> norepinephrine led to an increase in arterial blood pressure in WT animals that was sustained for the duration of drug administration. However, in  $\text{Kv}\beta 2^{-/-}$  mice, norepinephrine-induced elevation of pressure was not sustained, but declined after ~40 s of infusion. This inability to maintain elevated blood pressure during stress is reminiscent of effects in  $\text{Kv}1.5$ -null mice.<sup>12</sup> Therefore, as is the case with  $\text{Kv}1.5$ ,  $\text{Kv}\beta 2$  appears to play an essential role in supporting cardiac contractile performance under conditions of catecholamine stress and enhanced cardiac workload.

### Relationship between myocardial blood flow and cardiac workload is disrupted in $\text{Kv}\beta 2$ -null mice.

The inability of  $\text{Kv}\beta 2^{-/-}$  mice to sustain cardiac performance may reflect insufficient oxygen delivery during stress. Thus, we postulated that  $\text{Kv}\beta$  proteins may be integral to the relationship between myocardial blood flow (MBF) and cardiac workload. To test this, we used myocardial contrast echocardiography (MCE)<sup>11, 12</sup> to compare MBF in WT and  $\text{Kv}\beta$ -null mice. MCE uses high-power ultrasound to destruct lipid-shelled echogenic microbubbles in circulation. Subsequent replenishment of signal intensity in a region of interest following disruption is used to calculate the tissue perfusion (Figure 2A, see Methods). Because MBF responds to changes in ventricular workload and myocardial metabolic activity, we used MCE to evaluate MBF as a function of cardiac workload (i.e., double product of mean arterial blood pressure x heart rate),<sup>12</sup> monitored at baseline and during intermittent intravenous infusions of norepinephrine ( $0.5 - 5 \mu\text{g}/\text{kg}\cdot\text{min}^{-1}$ ). Figure 2B shows representative contrast signal intensities plotted over a period of ~10 s after microbubble destruction and fit with a one-phase exponential function (see *inset*) in WT (129SvEv),  $\text{Kv}\beta 1.1^{-/-}$ , and  $\text{Kv}\beta 2^{-/-}$  mice ( $5 \mu\text{g}/\text{kg}\cdot\text{min}^{-1}$  norepinephrine). The relationship between MBF and double product shows a modest elevation of MBF, albeit across a lower workload range in  $\text{Kv}\beta 1.1^{-/-}$  mice compared with WT mice (Figure 2C). However, consistent with impaired cardiac function under stress conditions described above (see Figure 1), levels of MBF recorded in  $\text{Kv}\beta 2^{-/-}$  mice were markedly reduced. Specifically, linear regression analysis showed a significant reduction in the slope of the MBF-work relationship in  $\text{Kv}\beta 2^{-/-}$  mice (Figure 2D). MAP, HR, and echocardiographic data at baseline and after acute norepinephrine infusion for each group are summarized in Online Figure I and Table I. Note that cardiac workload in  $\text{Kv}\beta 1.1^{-/-}$  mice was reduced due to lower MAP relative to corresponding wild type mice in the presence of  $1-5 \mu\text{g}/\text{kg}\cdot\text{min}^{-1}$  norepinephrine (see Figures 2C and Online Figure I). However, MAP, HR, and double product were not significantly different between WT and  $\text{Kv}\beta 2^{-/-}$  mice over the tested range of norepinephrine. Taken together, these data reflect differential roles for  $\text{Kv}\beta 1.1$  and  $\text{Kv}\beta 2$  proteins in regulating MBF, whereby loss of  $\text{Kv}\beta 2$  suppresses MBF and impairs cardiac function as the heart is subjected to increased workloads.

### Oxygen sensitivity of coronary arterial diameter is modified by Kv $\beta$ 2.

Impaired Kv1-mediated coronary vasodilation results in a markedly reduced myocardial oxygen tension during increased metabolic demand.<sup>22</sup> We therefore posited that coronary vasodilation in response to metabolic stress may be impaired by loss of Kv $\beta$ 2. Arteries of the systemic circulation exhibit robust dilation in response to metabolic stressors such as hypoxia and intracellular acidosis via a number of purported mechanisms, including activation of Kv channels.<sup>23, 24</sup> Hence, we examined the *ex vivo* vasoreactivity of coronary arteries isolated from WT and Kv $\beta$ 2<sup>-/-</sup> mice in response to an acute reduction in oxygen. When subjected to physiological intravascular pressures, isolated coronary arteries developed myogenic tone (i.e.,  $8 \pm 2\%$  and  $11 \pm 2\%$  at 60 and 80 mmHg, respectively). To evaluate vasodilatory capacity, arteries were pressurized (60 mmHg), pre-constricted with 100 nM U46619, and subjected to hypoxic bath conditions (physiological saline solution aerated with 95% N<sub>2</sub>/5% CO<sub>2</sub> and containing 1 mM hydrosulfite).<sup>25-27</sup> Direct measurement of bath O<sub>2</sub> levels confirmed a significant reduction in O<sub>2</sub> from control levels during application of hypoxic conditions (Figure 3A). As shown in Figure 3B (*top*) and Online Figure II, coronary arteries isolated from WT mice responded to hypoxic perfusate with robust and reversible dilation. Vasodilation was not observed when 1 mM hydrosulfite was applied in the presence of 20% O<sub>2</sub> (Online Figure II). Consistent with the involvement of Kv1 channels, the selective Kv1 inhibitor psora-4 (500 nM) significantly attenuated (~58%) hypoxia-induced vasodilation (Online Figure II). Likewise, hypoxia-induced dilation was significantly reduced in arteries from Kv $\beta$ 2<sup>-/-</sup> mice ( $19.6 \pm 6.4\%$ ) compared with arteries from WT mice ( $56.9 \pm 6.2\%$ ) (Figure 3B-D). Together, these data suggest that Kv $\beta$ 2 proteins facilitate vasodilation to reduced PO<sub>2</sub> and support the notion that Kv $\beta$  proteins link tissue perfusion to local oxygen consumption.

### L-lactate augments I<sub>KV</sub> in coronary arterial myocytes and induces coronary vasodilation via Kv $\beta$ 2.

We tested whether Kv1 activity in coronary arterial myocytes is sensitive to acute changes in oxygen due to alterations in cellular redox potential via elevation of L-lactate. Our reasoning for examining the effects of L-lactate was two-fold: first, myocardial underperfusion leads to a rapid decline in tissue PO<sub>2</sub>, increased anaerobic metabolism, and net accumulation of L-lactate that can promote feedback coronary vasodilation to increase MBF.<sup>21, 28-31</sup> Second, it is plausible that Kv1 channels, via association with Kv $\beta$  proteins, may be acutely responsive to changes in lactate secondary to modification of cellular NADH:NAD<sup>+</sup> ratio after uptake and interconversion to pyruvate via the lactate dehydrogenase reaction.<sup>15, 17, 32-35</sup> Consistent with this expectation, using the perforated whole cell configuration of the patch clamp technique, we observed a significant increase in outward K<sup>+</sup> current density (pA/pF) in isolated coronary arterial myocytes immediately following (1-3 min) application of 10 mM L-lactate in the bath (Figure 4A, C). However, this effect was abolished when L-lactate was applied in the presence of the Kv1 blocker psora-4 (500 nM, Figure 4B, D). The change in I<sub>K</sub> induced by application of 10 mM L-lactate in coronary arterial myocytes in the absence and presence of psora-4 is shown in Figure 4E. These data indicate that L-lactate acutely potentiates I<sub>KV</sub> in coronary arterial myocytes.

We next examined the vasodilatory response of precontracted coronary arteries to increasing concentrations of extracellular L-lactate. As shown in Figure 4F and consistent with previous studies,<sup>36, 37</sup> isolated coronary arteries that were pre-constricted with 100 nM U46619 exhibited step-wise vasodilation in response to elevation of external L-lactate (5–20 mM). This effect was abolished when L-lactate was applied in the presence of 500 nM psora-4 (Figure 4G, I), consistent with involvement of  $I_{K_V}$  described above. Furthermore, L-lactate-induced vasodilation was also abolished in arteries isolated from  $Kv\beta 2^{-/-}$  mice, indicating a key role for this subunit in L-lactate-induced vasodilation (Figure 4H, I). These data are consistent with the notion that the regulation of  $Kv\beta 2$  via vascular intermediary metabolism controls coronary vasodilatory function upon acute changes in myocardial oxygen tension.

### Functional role for $Kv\beta 2$ in L-lactate-induced vasodilation of resistance mesenteric arteries.

We next asked whether the role for  $Kv\beta$  in redox-dependent vasoreactivity is confined to the coronary vasculature or is generally observed in peripheral resistance arterial beds where  $Kv1$  prominently controls vascular tone. For this, we first compared  $Kv\beta$  protein-protein interactions in arterial myocytes of coronary versus mesenteric (3<sup>rd</sup> and 4<sup>th</sup> order) arteries using *in situ* proximity ligation (PLA), as previously described.<sup>18, 20, 38</sup> The PLA method is based on dual labelling of proteins that are located within close proximity (<40 nm), and thus, is an approach used to identify protein-protein interactions in complexes with molecular resolution. We observed robust PLA-associated fluorescent signals in coronary arterial myocytes that were co-labelled with  $Kv1.5$  and  $Kv1.2$ ,  $Kv1.5$  and  $Kv\beta 1$ ,  $Kv1.5$  and  $Kv\beta 2$ , or  $Kv\beta 1$  and  $Kv\beta 2$  (Figure 5A), consistent with heteromeric oligomerization of Shaker channels.<sup>20, 39</sup> The number of fluorescent sites assigned to these -  $\alpha/\alpha$ ,  $\alpha/\beta$ , and  $\beta/\beta$  interactions were similar between coronary and mesenteric arterial myocytes (Figure 5A, B). PLA-associated fluorescence in cells labeled for  $Kv1.5$  alone was negligible for arterial myocytes of both beds. These data suggest that  $Kv \alpha/\beta$  subunit expression patterns and interactions are similar in arterial myocytes of these two distinct vascular beds.

Next, we tested whether knockout of  $Kv\beta 1.1$  or  $Kv\beta 2$  alters the regulation of mesenteric arterial diameter. Note that ablation of either of these  $Kv\beta$  proteins had no statistically significant effect on the active (i.e., myogenic tone) or passive responses to increases in intravascular pressure, nor did it impact vasoconstriction responses to direct membrane potential depolarization with 60 mM  $K^+$  or the stable thromboxane  $A_2$  receptor agonist U46619 (100 nM; Online Figure III). Similar to observations in isolated coronary arteries (see Figure 4F), application of L-lactate (5–20 mM) resulted in robust and reversible dilation of isolated mesenteric arteries (Figure 5C). L-lactate-mediated vasodilation was insensitive to endothelial denudation but was abolished when arteries were constricted with elevated external  $K^+$ , rather than U46619 (Online Figure IV). Consistent with observations in isolated coronary arteries, vasodilation in response to L-lactate was eliminated by the  $Kv1$ -selective inhibitor psora-4 and loss of  $Kv\beta 2$  (Figure 5C-E). The dilatory response to L-lactate was not significantly different between arteries from  $Kv\beta 1.1^{-/-}$  mice when compared with arteries from corresponding WT animals (Online Figure V). Moreover, in contrast to the disparate effects of L-lactate, vasodilation induced by adenosine (1 – 100  $\mu$ M) was not significantly

different between  $Kv\beta 1.1^{-/-}$  or  $Kv\beta 2^{-/-}$  arteries, when compared with corresponding WT arterial preparations (Online Figure VI). Together with results shown in Figures 2–4, these data identify  $Kv\beta 2$  as a functional regulatory constituent of  $Kv1$  channels that imparts stimulus-dependent redox control of vascular tone.

### **Increasing the $Kv\beta 1.1$ : $Kv\beta 2$ ratio suppresses redox-dependent vasodilation and MBF.**

Native  $Kv1$  channels are comprised of pore-forming subunits associated with more than one  $Kv\beta$  subtype. This combinatorial variability may contribute to the diversity and cell-specific adaptability of channel function to a wide range of physiological and pathological stimuli. In coronary arterial myocytes, both  $Kv\beta 1.1$  and  $Kv\beta 2$  proteins are present in native  $Kv1$  auxiliary subunit complexes;<sup>20</sup> however, our data suggest that these proteins may have divergent roles in the regulation of arterial diameter and myocardial perfusion. That is, in contrast to our observations made in  $Kv\beta 2^{-/-}$  mice, deletion of  $Kv\beta 1.1$  did not impede MBF. Structural comparison of the two subunits shows a clear difference in the N-termini of  $Kv\beta 1$  and  $Kv\beta 2$  subunits. The N-termini of  $Kv\beta 1$  proteins form a ball-and-chain-like inactivation domain, a feature that is lacking in  $Kv\beta 2$ .<sup>17</sup> Thus, we hypothesized that the association of  $Kv\beta 1.1$  with  $Kv1$  channels may serve to counter the regulatory function imparted by  $Kv\beta 2$ . A testable prediction based on this hypothesis is that increasing the ratio of  $Kv\beta 1.1$ : $Kv\beta 2$  subunits in arterial myocytes would recapitulate the effects of  $Kv\beta 2$  deletion. To examine this possibility, we generated transgenic mice with conditional doxycycline-inducible overexpression of  $Kv\beta 1.1$  in smooth muscle cells (Figure 6A, see Methods). Briefly, this model consists of transgenic mice with a reverse tetracycline trans-activator driven by the  $SM22\alpha$  promoter ( $SM22\alpha$ -rtTA)<sup>40</sup> crossed to transgenic mice with  $Kcnab1$  downstream of the tetracycline responsive element (TRE- $Kv\beta 1$ ) to yield double transgenic ( $SM22\alpha$ -rtTA:TRE- $Kv\beta 1$ ) and single transgenic littermate control ( $SM22\alpha$ -rtTA) mice. Western blot revealed elevated  $Kv\beta 1$  protein abundance in arteries of  $SM22\alpha$ -rtTA:TRE- $Kv\beta 1$  mice after doxycycline treatment, compared with arteries from doxycycline-treated  $SM22\alpha$ -rtTA mice (Figure 6B,C). Consistent with a lack of doxycycline effects on  $Kv\beta 1$  protein in peripheral tissues, no statistically significant differences were observed in  $Kv\beta 1$ -associated band intensities in brain lysates of  $SM22\alpha$ -rtTA:TRE- $Kv\beta 1$  versus  $SM22\alpha$ -rtTA mice.

We next measured the relative levels of  $Kv1\alpha$ : $Kv\beta$  protein interactions in coronary arterial myocytes via PLA. We observed PLA-associated fluorescent punctae in coronary arterial myocytes from  $SM22\alpha$ -rtTA that were either co-labelled with  $Kv1.5$  and  $Kv\beta 1$ , or with  $Kv1.5$  and  $Kv\beta 2$ . Consistent with results of Western blot experiments described above, we observed a significant increase in  $Kv1.5$ : $Kv\beta 1$ -associated PLA signal in coronary arterial myocytes from  $SM22\alpha$ -rtTA:TRE- $Kv\beta 1$  when compared with myocytes from  $SM22\alpha$ -rtTA mice (Figure 6D, E). Notably,  $Kv1.5$ - $Kv\beta 2$ -associated PLA signal was reduced in myocytes from  $SM22\alpha$ -rtTA:TRE- $Kv\beta 1$  when compared with myocytes from  $SM22\alpha$ -rtTA mice, suggesting that double transgenic mice express vascular  $Kv1$  complexes with increased ratios of  $Kv\beta 1.1$ : $Kv\beta 2$  subunits. Functionally, enhanced  $Kv\beta 1.1$ : $Kv\beta 2$  subunit composition in arterial myocytes from  $SM22\alpha$ -rtTA:TRE- $Kv\beta 1$  was associated with significantly blunted vasodilation of isolated mesenteric arteries in response to extracellular L-lactate when compared with arteries from single transgenic control mice (Figure 6F, G). Indeed, these

observations in SM22 $\alpha$ -rtTA:TRE-Kv $\beta$ 1 arteries were similar to those made in coronary and mesenteric arteries from Kv $\beta$ 2 $^{-/-}$  mice, as well as arteries from WT mice pre-treated with the Kv1-selective inhibitor psora-4 (see Figure 4F-I and 5C-E). *In vivo* evaluation of the relationship between MBF and cardiac workload revealed significantly suppressed MBF in SM22 $\alpha$ -rtTA:TRE-Kv $\beta$ 1 mice when compared with SM22 $\alpha$ -rtTA mice (Figure 6H). No differences in heart rate or MAP were observed between groups of mice (Online Figure VII). Together, these results indicate that Kv $\beta$ 1.1 in arterial myocytes functions as an inhibitory regulator of vasodilation, and that the control of MBF is balanced on the juxtaposing functional influences of Kv $\beta$ 1.1 and Kv $\beta$ 2 proteins.

## DISCUSSION

In this study we identify vascular Kv $\beta$  proteins as key regulators of myocardial blood flow. Our findings suggest that the auxiliary Kv $\beta$  subunits impart oxygen sensitivity to Kv1 channel function, enabling them to trigger vasodilation in response to an increase in oxygen demand. A functional role of Kv $\beta$  proteins in imparting oxygen-sensitivity to Kv1 channels and thereby regulating vasodilation is supported by the following key findings: 1) Kv $\beta$ 2 $^{-/-}$  mice exhibit acute cardiac failure during administration of norepinephrine; 2) MBF is significantly suppressed across the physiological range of cardiac workload in Kv $\beta$ 2 $^{-/-}$  mice, yet is moderately enhanced in Kv $\beta$ 1.1 $^{-/-}$  mice; 3) vasodilation of isolated coronary arteries in response to hypoxia and elevation of extracellular L-lactate is strongly attenuated by loss of Kv $\beta$ 2; 4) whereas ablation of Kv $\beta$  proteins does not impact vasoconstriction of resistance caliber mesenteric arteries, vasodilation of these vessels in response to L-lactate is abolished by ablation of Kv $\beta$ 2, comparable to effects of Kv $\beta$ 2 deletion in coronary arteries; and 5) increasing the Kv $\beta$ 1.1:Kv $\beta$ 2 ratio in smooth muscle impairs L-lactate-induced vasodilation and suppresses MBF, similar to observations made in Kv $\beta$ 2 $^{-/-}$  arteries and mice. Collectively these results support the concept that Kv $\beta$ 1.1 and Kv $\beta$ 2 cooperatively control vascular function and regulate MBF upon changes in metabolic demand.

Kv1 channels belong to one of several Kv subfamilies that regulate membrane potential and  $[Ca^{2+}]_i$  in arterial myocytes to control vessel diameter and blood flow.<sup>41</sup> Pharmacological blockade of Kv1 channels reduces whole-cell outward  $I_K$  by 50%,<sup>42</sup> whereas increased steady-state  $I_{Kv}$  results in membrane hyperpolarization and reduced  $Ca^{2+}$  influx via voltage-gated  $Ca^{2+}$  channels.<sup>43</sup> The resultant reduction in cytosolic  $[Ca^{2+}]_i$  leading to myocyte relaxation, and vasodilation increases local tissue perfusion. Considering the relatively high resting input resistance (1–10 G $\Omega$ ) of arterial smooth muscle cells, the opening or closure of few  $K^+$  channels can generate substantial changes in membrane potential and vascular tone.<sup>44, 45</sup> Consequently, the functional expression of native Kv channels of arterial myocytes is dynamically controlled by multiple molecular processes, which include post-transcriptional regulation (e.g., phosphorylation, glycosylation), subcellular trafficking and recycling, redox modifications, as well as association with accessory subunits and regulatory proteins.<sup>21, 31, 46–48</sup> Adding to this complexity, our observation that deletion of Kv $\beta$ 2 disrupts Kv1-dependent vasodilation is consistent with a functional role of this subunit in regulating the vasodilatory response to metabolic stress.



Kv channels in excitable cells assemble as either homomeric or heteromeric structures with varied  $\alpha_4\beta_4$  configurations of pore-forming and auxiliary subunits.<sup>49–52</sup> This ‘mix-and-match’ capability of Kv channels contributes to the wide heterogeneity of  $K^+$  currents that enables diverse physiological roles across different cell types. In our previous work we found that Kv1 channels in murine coronary arterial myocytes interact with Kv $\beta$ 1.1/Kv $\beta$ 2 heteromers,<sup>20</sup> and our present findings suggest a divergent functional regulation of vascular tone and blood flow by these proteins. These divergent roles are revealed by the observation that even though Kv $\beta$ 2 ablation suppressed vasodilatory function and MBF, the loss of Kv $\beta$ 1.1 had little impact on arterial diameter *ex vivo*, but elevated MBF *in vivo*. These findings suggest that Kv $\beta$ 1 and  $\beta$ 2 have somewhat divergent and potentially antagonist roles, which may relate to differences in their structures. The Kv $\beta$ 1 has a ball-and-chain inactivation domain at the N-terminus, a feature that is lacking in Kv $\beta$ 2. Potentially as a result of these differences, individual subunits have differential effects on the gating of non- and slowly-inactivating Kv1 $\alpha$  channels.<sup>53</sup> Specifically, Kv $\beta$ 1 induces N-type inactivation in non-inactivating Kv1 $\alpha$  proteins whereas Kv $\beta$ 2 increases current amplitude and shifts the voltage-dependence of activation towards more hyperpolarized potentials, with little impact on channel inactivation.<sup>15, 32, 53</sup> These effects are consistent with a greater steady-state activity of non-inactivating Kv1 $\alpha$  channels (e.g., Kv1.5) when assembled with Kv $\beta$ 2, as compared with those predominantly consisting of Kv $\beta$ 1 proteins.

How the net competing influences of multiple Kv $\beta$  subtypes impact the function of native Kv1 channels remains to be resolved; however, it has been reported that within the same auxiliary complex, the N-terminal inactivation function of Kv $\beta$ 1 is inhibited by Kv $\beta$ 2 subunits,<sup>54</sup> an effect which may be due to competition between Kv $\beta$  subtypes for the intracellular domain of pore-forming Shaker subunits, or through modification of Kv $\beta$ 1 function via  $\beta$ : $\beta$  subunit interactions. We found that in arterial myocytes both Kv $\beta$ 1.1 and Kv $\beta$ 2 proteins are expressed in native Kv1 channels, and therefore, it is plausible that the greater abundance of Kv $\beta$ 2 relative to Kv $\beta$ 1.1 in Kv1 channels of coronary arterial myocytes underlies its functional dominance under physiological conditions. Consistent with this are the apparent differences in inactivation kinetics between slowly inactivating outward  $K^+$  currents measured in coronary arterial myocytes in comparison with rapidly inactivating (i.e., A-type) currents recorded in retinal arteriolar myocytes, which predominantly express Kv1.5 + Kv $\beta$ 1 proteins.<sup>55–57</sup> Indeed, our current data obtained from novel double transgenic mice overexpressing Kv $\beta$ 1.1 in smooth muscle suggest that increased abundance of Kv $\beta$ 1 proteins effectively diminishes the vasodilatory function attributed to Kv $\beta$ 2. Thus, based on these findings, we speculate that Kv $\beta$ 1 and  $\beta$ 2 play antagonistic roles and that Kv channel remodeling which results in functional upregulation of Kv $\beta$ 1.1 or downregulation of Kv $\beta$ 2 (i.e., elevated Kv $\beta$ 1.1:Kv $\beta$ 2 ratio) could impair vasodilation and limit tissue perfusion.

The Kv $\beta$  proteins were discovered as functional AKRs, a group of enzymes that catalyze the reduction of carbonyl compounds by NAD(P)H.<sup>58, 59</sup> In our previous work, we found that the binding of oxidized and reduced pyridine nucleotides to Kv $\beta$  proteins differentially modifies channel gating,<sup>15, 18, 32, 60, 61</sup> thus, raising the possibility that the Kv $\beta$  subunits provide a molecular link between the metabolic state of a cell and Kv channel activity. Given the high affinity of Kv $\beta$  proteins for pyridine nucleotides,<sup>14, 62</sup> it is plausible that rapid changes in intracellular redox potential of pyridine nucleotides in arterial myocytes

may underlie Kv-mediated control of blood flow in the heart upon changes in metabolic demand. We recently reported that Kv $\beta$ 2 subunits facilitate surface expression of Kv1 and Kv4 channels in cardiomyocytes and that they impart redox and metabolic sensitivity to cardiac Kv channels, thus coupling repolarization with intracellular pyridine nucleotide redox status;<sup>18</sup> however, to the best of our knowledge, the current study is the first to suggest a fundamental role for these subunits in controlling resistance vascular tone and blood flow.

Although our data show that Kv $\beta$  proteins regulate the diameter of resistance arteries subsequent to the modulation of NAD(H) redox via elevation of L-lactate, the precise identity of the factors responsible for coupling between myocardial oxygen consumption and coronary arterial tone remain unclear. Several myocardium-derived ‘metabolites’ (e.g., local O<sub>2</sub>/CO<sub>2</sub> tensions, reactive oxygen species such as H<sub>2</sub>O<sub>2</sub>, lactate, endothelial-derived factors such as arachidonic acid metabolites)<sup>9</sup> could conceivably alter intracellular pyridine nucleotide redox potential and further work is required to identify specific metabolic processes that link intracellular redox changes to Kv activity. The function of coronary Kv1 channels could also be affected by other long-term biochemical processes. For example, the Kv $\beta$  proteins could plausibly alter patterns of basal post-transcriptional regulatory pathways (e.g., PKC-mediated channel phosphorylation)<sup>63</sup> or the surface density of functional channels. However, such differences would likely manifest as differences in myogenic tone development or differential responses to vasoconstrictor stimuli,<sup>64</sup> which were not seen in our study, suggesting that the vasoregulatory effects of Kv $\beta$  may reflect more dynamic modifications of channel function.

Even though our study has many strengths, some limitations should be considered. Our studies were performed in mice, which exhibit greater heart rates and MBF relative to larger mammals, including humans.<sup>65</sup> Nonetheless, the positive correlation between myocardial oxygen consumption and MBF is highly conserved across species, and the parallel importance of Kv1 channels in the regulation of MBF is established in small rodents and larger mammals (i.e., swine).<sup>11–13</sup> Thus, it is likely that regulation of MBF by Kv $\beta$  proteins, observed in our current study, extends to larger species. Additionally, we cannot exclude the possibility that deletion of Kv $\beta$  proteins in non-vascular cell types (e.g., cardiomyocytes, neurons) may contribute to effects on MBF *in vivo*. However, this is unlikely for several reasons. First, prior work from our group indicates that suppression of blood flow in animals lacking Kv1.5, a predominant Kv1 $\alpha$  binding partner of Kv $\beta$ , is restored via its conditional reconstitution in smooth muscle.<sup>12</sup> Second, data from novel transgenic mice generated for the current study (SM22 $\alpha$ -rtTA:TRE-Kv $\beta$ 1) indicate that smooth muscle-selective overexpression of Kv $\beta$ 1.1, which increases the ratio of Kv $\beta$ 1.1:Kv $\beta$ 2 subunits in native Kv1 channels in arterial myocytes, leads to robust suppression of vasodilation and MBF, similar to observations in global Kv $\beta$ 2 knockout mice. Additional evidence from *ex vivo* arterial diameter measurements further supports the role for vascular Kv $\beta$  proteins in the regulation of vasoreactivity and is consistent with the notion that Kv $\beta$  subunits of native arterial Kv1 channels facilitate the metabolic hyperemia response.

In summary, we report a novel role for intracellular Kv $\beta$  subunits in the differential regulation of resistance artery diameter and control of myocardial blood flow. Our results indicate that proper coupling between coronary arterial diameter and myocardial oxygen

consumption relies on the molecular composition of Kv1 accessory subunit complexes such that the functional expression of Kv $\beta$ 2 is essential for Kv1-mediated vasodilation. Moreover, the current study suggests that perturbations in Kv $\beta$  function or expression profile (i.e., Kv $\beta$ 1.1:Kv $\beta$ 2) may underlie the dysregulation of blood flow in disease states characterized by impaired microvascular function and ischemia-related cardiac dysfunction.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGEMENTS

We thank Mr. Donald Mosley and Mr. Zachary Wohl for technical assistance and Mr. Daniel Riggs for statistical assistance.

### SOURCES OF FUNDING

This work was supported by grants from the National Institutes of Health (HL142710, GM103492), American Heart Association (16SDG27260070), and the University of Louisville, School of Medicine.

## Nonstandard Abbreviations and Acronyms:

<b>I<sub>K</sub></b>	Potassium current
<b>Kv</b>	Voltage-gated potassium channel
<b>Kv<math>\beta</math></b>	Voltage-gated potassium channel beta protein
<b>MBF</b>	Myocardial blood flow
<b>MCE</b>	Myocardial contrast echocardiography
<b>NAD</b>	Nicotinamide adenine dinucleotide
<b>NADH</b>	Nicotinamide adenine dinucleotide (reduced)
<b>rtTA</b>	Reverse tetracycline response element
<b>SM22<math>\alpha</math></b>	Smooth muscle actin 22 alpha
<b>TRE</b>	Tetracycline response element
<b>WT</b>	Wild type

## REFERENCES

1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW, American Heart Association Council on E, Prevention Statistics C, Stroke Statistics S. Heart disease and stroke statistics-2020 update: A report from the american heart association. *Circulation*. 2020:CIR0000000000000757

2. Tsagalou EP, Anastasiou-Nana M, Agapitos E, Gika A, Drakos SG, Terrovitis JV, Ntalianis A, Nanas JN. Depressed coronary flow reserve is associated with decreased myocardial capillary density in patients with heart failure due to idiopathic dilated cardiomyopathy. *Journal of the American College of Cardiology*. 2008;52:1391–1398 [PubMed: 18940529]
3. Brush JE Jr., Cannon RO 3rd, Schenke WH, Bonow RO, Leon MB, Maron BJ, Epstein SE. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. *The New England journal of medicine*. 1988;319:1302–1307 [PubMed: 3185633]
4. Di Carli MF, Charytan D, McMahon GT, Ganz P, Dorbala S, Schelbert HR. Coronary circulatory function in patients with the metabolic syndrome. *J Nucl Med*. 2011;52:1369–1377 [PubMed: 21849399]
5. Fukuda D, Yoshiyama M, Shimada K, Yamashita H, Ehara S, Nakamura Y, Kamimori K, Tanaka A, Kawarabayashi T, Yoshikawa J. Relation between aortic stiffness and coronary flow reserve in patients with coronary artery disease. *Heart*. 2006;92:759–762 [PubMed: 16216858]
6. Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM, Johnson BD, Sopko G, Bairey Merz CN. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the national heart, lung and blood institute wise (women's ischemia syndrome evaluation) study. *Journal of the American College of Cardiology*. 2010;55:2825–2832 [PubMed: 20579539]
7. Merz CN, Kelsey SF, Pepine CJ, Reichek N, Reis SE, Rogers WJ, Sharaf BL, Sopko G. The women's ischemia syndrome evaluation (wise) study: Protocol design, methodology and feasibility report. *Journal of the American College of Cardiology*. 1999;33:1453–1461 [PubMed: 10334408]
8. Feigl EO. Coronary physiology. *Physiol Rev*. 1983;63:1–205 [PubMed: 6296890]
9. Goodwill AG, Dick GM, Kiel AM, Tune JD. Regulation of coronary blood flow. *Compr Physiol*. 2017;7:321–382 [PubMed: 2833376]
10. Binak K, Harmanci N, Sirmaci N, Ataman N, Ogan H. Oxygen extraction rate of the myocardium at rest and on exercise in various conditions. *Br Heart J*. 1967;29:422–427 [PubMed: 6023735]
11. Ohanyan V, Yin L, Bardakjian R, Kolz C, Enrick M, Hakobyan T, Luli J, Graham K, Khayata M, Logan S, Kmetz J, Chilian WM. Kv1.3 channels facilitate the connection between metabolism and blood flow in the heart. *Microcirculation*. 2017;24
12. Ohanyan V, Yin L, Bardakjian R, Kolz C, Enrick M, Hakobyan T, Kmetz J, Bratz I, Luli J, Nagane M, Khan N, Hou H, Kuppusamy P, Graham J, Fu FK, Janota D, Oyewumi MO, Logan S, Lindner JR, Chilian WM. Requisite role of kv1.5 channels in coronary metabolic dilation. *Circulation research*. 2015;117:612–621 [PubMed: 26224794]
13. Goodwill AG, Noblet JN, Sassoon D, Fu L, Kassab GS, Schepers L, Herring BP, Rottgen TS, Tune JD, Dick GM. Critical contribution of kv1 channels to the regulation of coronary blood flow. *Basic Res Cardiol*. 2016;111:56 [PubMed: 27496159]
14. Liu SQ, Jin H, Zacarias A, Srivastava S, Bhatnagar A. Binding of pyridine nucleotide coenzymes to the beta-subunit of the voltage-sensitive k<sup>+</sup> channel. *The Journal of biological chemistry*. 2001;276:11812–11820
15. Tipparaju SM, Saxena N, Liu SQ, Kumar R, Bhatnagar A. Differential regulation of voltage-gated k<sup>+</sup> channels by oxidized and reduced pyridine nucleotide coenzymes. *American journal of physiology. Cell physiology*. 2005;288:C366–376 [PubMed: 15469953]
16. Kilfoil PJ, Tipparaju SM, Barski OA, Bhatnagar A. Regulation of ion channels by pyridine nucleotides. *Circulation research*. 2013;112:721–741 [PubMed: 23410881]
17. Pongs O, Schwarz JR. Ancillary subunits associated with voltage-dependent k<sup>+</sup> channels. *Physiol Rev*. 2010;90:755–796 [PubMed: 20393197]
18. Kilfoil PJ, Chapalamadugu KC, Hu X, Zhang D, Raucis FJ Jr., Tur J, Brittan KR, Jones SP, Bhatnagar A, Tipparaju SM, Nystoriak MA. Metabolic regulation of kv channels and cardiac repolarization by kvbeta2 subunits. *Journal of molecular and cellular cardiology*. 2019;137:93–106 [PubMed: 31639389]
19. Nishijima Y, Korishettar A, Chabowski DS, Cao S, Zheng X, Gutterman DD, Zhang DX. Shaker-related voltage-gated k(+) channel expression and vasomotor function in human coronary resistance arteries. *Microcirculation*. 2018;25

20. Nystoriak MA, Zhang D, Jagatheesan G, Bhatnagar A. Heteromeric complexes of aldo-keto reductase auxiliary kvbeta subunits (akr6a) regulate sarcolemmal localization of kv1.5 in coronary arterial myocytes. *Chem Biol Interact.* 2017
21. Dwenger MM, Ohanyan V, Navedo MF, Nystoriak MA. Coronary microvascular kv1 channels as regulatory sensors of intracellular pyridine nucleotide redox potential. *Microcirculation.* 2018;25
22. Ohanyan V, Yin L, Bardakjian R, Kolz C, Enrick M, Hakobyan T, Kmetz J, Bratz I, Luli J, Nagane M, Khan N, Hou H, Kuppusamy P, Graham J, Fu FK, Janota D, Oyewumi MO, Logan S, Lindner JR, Chilian WM. Requisite role of kv1.5 channels in coronary metabolic dilation. *Circulation research.* 2015;117:612–621 [PubMed: 26224794]
23. Hedegaard ER, Nielsen BD, Kun A, Hughes AD, Kroigaard C, Mogensen S, Matchkov VV, Frobert O, Simonsen U. Kv 7 channels are involved in hypoxia-induced vasodilatation of porcine coronary arteries. *British journal of pharmacology.* 2014;171:69–82 [PubMed: 24111896]
24. Berger MG, Vandier C, Bonnet P, Jackson WF, Rusch NJ. Intracellular acidosis differentially regulates kv channels in coronary and pulmonary vascular muscle. *The American journal of physiology.* 1998;275:H1351–1359
25. Clements RT, Sodha NR, Feng J, Boodhwani M, Liu Y, Mieno S, Khabbaz KR, Bianchi C, Sellke FW. Impaired coronary microvascular dilation correlates with enhanced vascular smooth muscle mlc phosphorylation in diabetes. *Microcirculation.* 2009;16:193–206 [PubMed: 19152178]
26. Otter D, Austin C. Mechanisms of hypoxic vasodilatation of isolated rat mesenteric arteries: A comparison with metabolic inhibition. *The Journal of physiology.* 1999;516 ( Pt 1):249–259 [PubMed: 10066938]
27. Otter D, Austin C. Hypoxia, metabolic inhibition, and isolated rat mesenteric tone: Influence of arterial diameter. *Microvasc Res.* 2000;59:107–114 [PubMed: 10625577]
28. Dunn RB, Griggs DM Jr., Transmural gradients in ventricular tissue metabolites produced by stopping coronary blood flow in the dog. *Circulation research.* 1975;37:438–445 [PubMed: 1182935]
29. Hester RK, Weiss GB, Willerson JT. Basis of ph-independent inhibitory effects of lactate on 45ca movements and responses to kcl and pgf2 alpha in canine coronary arteries. *Circulation research.* 1980;46:771–779 [PubMed: 7379243]
30. Archer SL, Weir EK, Reeve HL, Michelakis E. Molecular identification of o2 sensors and o2-sensitive potassium channels in the pulmonary circulation. *Adv Exp Med Biol.* 2000;475:219–240 [PubMed: 10849663]
31. Rogers PA, Dick GM, Knudson JD, Focardi M, Bratz IN, Swafford AN Jr., Saitoh S, Tune JD, Chilian WM. H2o2-induced redox-sensitive coronary vasodilation is mediated by 4-aminopyridine-sensitive k+ channels. *American journal of physiology. Heart and circulatory physiology.* 2006;291:H2473–2482
32. Tipparaju SM, Li XP, Kilfoil PJ, Xue B, Uversky VN, Bhatnagar A, Barski OA. Interactions between the c-terminus of kv1.5 and kvbeta regulate pyridine nucleotide-dependent changes in channel gating. *Pflugers Arch.* 2012;463:799–818 [PubMed: 22426702]
33. Rettig J, Heinemann SH, Wunder F, Lorra C, Parcej DN, Dolly JO, Pongs O. Inactivation properties of voltage-gated k+ channels altered by presence of beta-subunit. *Nature.* 1994;369:289–294 [PubMed: 8183366]
34. Sun F, Dai C, Xie J, Hu X. Biochemical issues in estimation of cytosolic free nad/nadh ratio. *PLoS one.* 2012;7:e34525
35. Williamson DH, Lund P, Krebs HA. The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. *Biochem J.* 1967;103:514–527 [PubMed: 4291787]
36. Frobert O, Mikkelsen EO, Bagger JP, Gravholt CH. Measurement of interstitial lactate during hypoxia-induced dilatation in isolated pressurised porcine coronary arteries. *The Journal of physiology.* 2002;539:277–284 [PubMed: 11850519]
37. Chen YL, Wolin MS, Messina EJ. Evidence for cgmp mediation of skeletal muscle arteriolar dilation to lactate. *J Appl Physiol (1985).* 1996;81:349–354 [PubMed: 8828684]
38. Nystoriak MA, Nieves-Cintrón M, Patriarchi T, Buonarati OR, Prada MP, Morotti S, Grandi E, Fernandes JD, Forbush K, Hofmann F, Sasse KC, Scott JD, Ward SM, Hell JW, Navedo MF.

- Ser1928 phosphorylation by pka stimulates the l-type  $ca^{2+}$  channel *cav1.2* and vasoconstriction during acute hyperglycemia and diabetes. *Sci Signal*. 2017;10
39. Parcej DN, Scott VE, Dolly JO. Oligomeric properties of alpha-dendrotoxin-sensitive potassium ion channels purified from bovine brain. *Biochemistry*. 1992;31:11084–11088
  40. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM. Pulmonary hypertension in transgenic mice expressing a dominant-negative *bmprii* gene in smooth muscle. *Circulation research*. 2004;94:1109–1114 [PubMed: 15031260]
  41. Jackson WF. Kv channels and the regulation of vascular smooth muscle tone. *Microcirculation*. 2018;25
  42. Cox RH, Fromme S. Functional expression profile of voltage-gated  $k^{+}$  channel subunits in rat small mesenteric arteries. *Cell Biochem Biophys*. 2016;74:263–276 [PubMed: 27286858]
  43. Knot HJ, Nelson MT. Regulation of membrane potential and diameter by voltage-dependent  $k^{+}$  channels in rabbit myogenic cerebral arteries. *The American journal of physiology*. 1995;269:H348–355. [PubMed: 7631867]
  44. Nelson MT, Patlak JB, Worley JF, Standen NB. Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. *The American journal of physiology*. 1990;259:C3–18. [PubMed: 2164782]
  45. Aaronson PI, Bolton TB, Lang RJ, MacKenzie I. Calcium currents in single isolated smooth muscle cells from the rabbit ear artery in normal-calcium and high-barium solutions. *The Journal of physiology*. 1988;405:57–75 [PubMed: 2475611]
  46. Aiello EA, Malcolm AT, Walsh MP, Cole WC. Beta-adrenoceptor activation and pka regulate delayed rectifier  $k^{+}$  channels of vascular smooth muscle cells. *The American journal of physiology*. 1998;275:H448–459 [PubMed: 9683432]
  47. Andersen MN, Skibsbye L, Tang C, Petersen F, MacAulay N, Rasmussen HB, Jespersen T. Pkc and ampk regulation of *kv1.5* potassium channels. *Channels (Austin)*. 2015;9:121–128 [PubMed: 26043299]
  48. Cheang WS, Wong WT, Shen B, Lau CW, Tian XY, Tsang SY, Yao X, Chen ZY, Huang Y. 4-aminopyridine-sensitive  $k^{+}$  channels contributes to na<sub>h</sub>s-induced membrane hyperpolarization and relaxation in the rat coronary artery. *Vascul Pharmacol*. 2010;53:94–98 [PubMed: 20430111]
  49. Christie MJ, North RA, Osborne PB, Douglass J, Adelman JP. Heteropolymeric potassium channels expressed in *xenopus* oocytes from cloned subunits. *Neuron*. 1990;4:405–411 [PubMed: 2317379]
  50. Ruppertsberg JP, Schroter KH, Sakmann B, Stocker M, Sewing S, Pongs O. Heteromultimeric channels formed by rat brain potassium-channel proteins. *Nature*. 1990;345:535–537 [PubMed: 2348860]
  51. McCormack K, Lin JW, Iverson LE, Rudy B. Shaker  $k^{+}$  channel subunits from heteromultimeric channels with novel functional properties. *Biochemical and biophysical research communications*. 1990;171:1361–1371 [PubMed: 1699527]
  52. Zhu J, Watanabe I, Gomez B, Thornhill WB. Heteromeric *kv1* potassium channel expression: Amino acid determinants involved in processing and trafficking to the cell surface. *The Journal of biological chemistry*. 2003;278:25558–25567
  53. Accili EA, Kiehn J, Yang Q, Wang Z, Brown AM, Wible BA. Separable *kvbeta* subunit domains alter expression and gating of potassium channels. *The Journal of biological chemistry*. 1997;272:25824–25831
  54. Xu J, Li M. *Kvbeta2* inhibits the *kvbeta1*-mediated inactivation of  $k^{+}$  channels in transfected mammalian cells. *The Journal of biological chemistry*. 1997;272:11728–11735
  55. McGahon MK, Dawicki JM, Scholfield CN, McGeown JG, Curtis TM. A-type potassium current in retinal arteriolar smooth muscle cells. *Invest Ophthalmol Vis Sci*. 2005;46:3281–3287 [PubMed: 16123430]
  56. McGahon MK, Dawicki JM, Arora A, Simpson DA, Gardiner TA, Stitt AW, Scholfield CN, McGeown JG, Curtis TM. *Kv1.5* is a major component underlying the a-type potassium current in retinal arteriolar smooth muscle. *American journal of physiology. Heart and circulatory physiology*. 2007;292:H1001–1008

57. Rogers PA, Chilian WM, Bratz IN, Bryan RM Jr., Dick GM. H<sub>2</sub>O<sub>2</sub> activates redox- and 4-aminopyridine-sensitive kv channels in coronary vascular smooth muscle. *American journal of physiology. Heart and circulatory physiology.* 2007;292:H1404–1411
58. McCormack T, McCormack K. Shaker k<sup>+</sup> channel beta subunits belong to an nad(p)h-dependent oxidoreductase superfamily. *Cell.* 1994;79:1133–1135 [PubMed: 8001150]
59. Tipparaju SM, Barski OA, Srivastava S, Bhatnagar A. Catalytic mechanism and substrate specificity of the beta-subunit of the voltage-gated potassium channel. *Biochemistry.* 2008;47:8840–8854 [PubMed: 18672894]
60. Weng J, Cao Y, Moss N, Zhou M. Modulation of voltage-dependent shaker family potassium channels by an aldo-keto reductase. *The Journal of biological chemistry.* 2006;281:15194–15200
61. Pan Y, Weng J, Levin EJ, Zhou M. Oxidation of nadph on kvbeta1 inhibits ball-and-chain type inactivation by restraining the chain. *Proceedings of the National Academy of Sciences of the United States of America.* 2011;108:5885–5890 [PubMed: 21436029]
62. Tipparaju SM, Liu SQ, Barski OA, Bhatnagar A. Nadph binding to beta-subunit regulates inactivation of voltage-gated k<sup>(+)</sup> channels. *Biochemical and biophysical research communications.* 2007;359:269–276 [PubMed: 17540341]
63. Liu SQ, Yin J, Bhatnagar A. Protein kinase c-dependent phosphorylation of the beta-subunit of the voltage-sensitive potassium channels (kvbeta2). *Chem Biol Interact.* 2003;143–144:597–604
64. Hasan R, Jaggar JH. Kv channel trafficking and control of vascular tone. *Microcirculation.* 2018;25
65. Tune JD, Goodwill AG, Kiel AM, Baker HE, Bender SB, Merkus D, Duncker DJ. Disentangling the gordian knot of local metabolic control of coronary blood flow. *American journal of physiology. Heart and circulatory physiology.* 2020;318:H11–H24 [PubMed: 31702972]
66. Giese KP, Storm JF, Reuter D, Fedorov NB, Shao LR, Leicher T, Pongs O, Silva AJ. Reduced k<sup>+</sup> channel inactivation, spike broadening, and after-hyperpolarization in kvbeta1.1-deficient mice with impaired learning. *Learn Mem.* 1998;5:257–273 [PubMed: 10454353]
67. McCormack K, Connor JX, Zhou L, Ho LL, Ganetzky B, Chiu SY, Messing A. Genetic analysis of the mammalian k<sup>+</sup> channel beta subunit kvbeta 2 (kcnab2). *The Journal of biological chemistry.* 2002;277:13219–13228
68. Tsang SY, Yao X, Wong CM, Chan FL, Chen ZY, Huang Y. Differential regulation of k<sup>+</sup> and ca<sup>2+</sup> channel gene expression by chronic treatment with estrogen and tamoxifen in rat aorta. *Eur J Pharmacol.* 2004;483:155–162 [PubMed: 14729103]
69. Wei K, Skyba DM, Firsichke C, Jayaweera AR, Lindner JR, Kaul S. Interactions between microbubbles and ultrasound: In vitro and in vivo observations. *Journal of the American College of Cardiology.* 1997;29:1081–1088 [PubMed: 9120163]
70. Kaufmann PA, Gnecci-Ruscone T, Schafers KP, Luscher TF, Camici PG. Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. *Journal of the American College of Cardiology.* 2000;36:103–109 [PubMed: 10898420]
71. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. *Circulation.* 1998;97:473–483. [PubMed: 9490243]
72. Vogel R, Indermuhle A, Reinhardt J, Meier P, Siegrist PT, Namdar M, Kaufmann PA, Seiler C. The quantification of absolute myocardial perfusion in humans by contrast echocardiography: Algorithm and validation. *Journal of the American College of Cardiology.* 2005;45:754–762 [PubMed: 15734622]
73. Coggins MP, Sklenar J, Le DE, Wei K, Lindner JR, Kaul S. Noninvasive prediction of ultimate infarct size at the time of acute coronary occlusion based on the extent and magnitude of collateral-derived myocardial blood flow. *Circulation.* 2001;104:2471–2477 [PubMed: 11705827]
74. Raheer MJ, Thibault H, Poh KK, Liu R, Halpern EF, Derumeaux G, Ichinose F, Zapol WM, Bloch KD, Picard MH, Scherrer-Crosbie M. In vivo characterization of murine myocardial perfusion with myocardial contrast echocardiography: Validation and application in nitric oxide synthase 3 deficient mice. *Circulation.* 2007;116:1250–1257 [PubMed: 17709634]
75. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence of absence of asynergy. *The American journal of cardiology.* 1976;37:7–11 [PubMed: 1244736]

76. van de Weijer T, van Ewijk PA, Zandbergen HR, Slenter JM, Kessels AG, Wildberger JE, Hesselink MK, Schrauwen P, Schrauwen-Hinderling VB, Kooi ME. Geometrical models for cardiac mri in rodents: Comparison of quantification of left ventricular volumes and function by various geometrical models with a full-volume mri data set in rodents. *American journal of physiology. Heart and circulatory physiology.* 2012;302:H709–715 [PubMed: 22101529]
77. Nystoriak MA, O'Connor KP, Sonkusare SK, Brayden JE, Nelson MT, Wellman GC. Fundamental increase in pressure-dependent constriction of brain parenchymal arterioles from subarachnoid hemorrhage model rats due to membrane depolarization. *American journal of physiology. Heart and circulatory physiology.* 2011;300:H803–812 [PubMed: 21148767]
78. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, Wester K, Hydbring P, Bahram F, Larsson LG, Landegren U. Direct observation of individual endogenous protein complexes in situ by proximity ligation. *Nat Methods.* 2006;3:995–1000 [PubMed: 17072308]



## NOVELTY AND SIGNIFICANCE


### What Is Known?

- Inadequate myocardial perfusion resulting from impaired coronary vasodilation contributes to cardiovascular morbidity and mortality.
- The coronary arteries and arterioles dilate in response to local increases in myocardial oxygen demand in a process that requires smooth muscle voltage-gated potassium (Kv) channels.
- The molecular components of native Kv channels that impart oxygen sensitivity to coronary vascular tone are unknown.

### What New Information Does This Article Contribute?


- The intracellular Kv subunit complex (i.e., Kv $\beta$  proteins) in coronary arterial smooth muscle is an essential regulator of myocardial perfusion.
- Ablation of Kv $\beta$ 2 proteins in mice suppresses the relationship between myocardial blood flow and cardiac workload in vivo, and attenuates the oxygen-sensitivity of vascular tone ex vivo.
- Driving an overabundance of Kv $\beta$ 1.1 proteins in smooth muscle recapitulates the effects of Kv $\beta$ 2 ablation, indicating the contrasting regulatory roles for Kv $\beta$ 1 and Kv $\beta$ 2 proteins within heteromeric vascular Kv1 complexes.

Dynamic changes in the diameter of coronary arteries and arterioles are required to closely match oxygen supply (i.e., blood flow) with the metabolic demands of the heart. Coronary vasodilation and elevated myocardial flow upon acute increases in cardiac workload (e.g., during exercise) requires Kv1 channels expressed in vascular smooth muscle cells. Nonetheless, how vascular Kv1 channels sense changes in oxygen demand to regulate blood flow to active myocardium is unresolved. In this study, we report that the regulation of myocardial blood flow by Kv1 channels is controlled by the intracellular Kv $\beta$  protein complex interacting with the membrane-bound pore of the channel. The Kv $\beta$  proteins bind cytosolic pyridine nucleotides and differentially regulate channel gating behavior in a redox-dependent manner. Our results support the concept that Kv $\beta$ 1.1:Kv $\beta$ 2 heteromeric complexes that interact with native Kv1 channels (e.g., Kv1.5) fine-tune channel responsiveness to changes in metabolic demand by contributing opposing regulatory roles, such that Kv $\beta$ 2 enhances and Kv $\beta$ 1.1 inhibits Kv-mediated oxygen-dependent coronary vasodilation. Our study has broad implications for future mechanistic investigations into how the metabolic hyperemia response is modified at the molecular level during disease development and progression.




**Figure 1: Loss of  $Kv\beta 2$  impairs cardiac pump function during stress.**

(A) Representative M-mode echocardiographic images obtained from wild type (WT; 129SvEv), and  $Kv\beta 2^{-/-}$  mice during infusion of  $5\ \mu\text{g}/\text{kg}\cdot\text{min}^{-1}$  norepinephrine. (B) Box-and-whisker plot of ejection fraction data for WT and  $Kv\beta 2^{-/-}$  mice at baseline, after administration of hexamethonium (HX;  $5\ \text{mg}\cdot\text{kg}^{-1}$ , i.v.), and during norepinephrine infusions ( $0.5 - 5\ \mu\text{g}/\text{kg}\cdot\text{min}^{-1}$ ; 2–3 min duration).  $n = 8$  each,  $**P < 0.01$ ,  $***P < 0.001$  (two-way RM ANOVA). (C) Arterial blood pressure recordings obtained via femoral artery catheter in WT and  $Kv\beta 2^{-/-}$  mice, before and after norepinephrine treatment (NE,  $5\ \mu\text{g}/\text{kg}\cdot\text{min}^{-1}$ , indicated by arrows).




**Figure 2: Relationship between myocardial blood flow and cardiac workload in Kvβ-null mice.**

(A) Long axis MCE images showing signal intensity from myocardial tissue and cavity before destruction frame and during replenishment phase (~10 sec). The left ventricular wall is outlined with a yellow dashed line in the destruction frame. (B) Signal intensity versus time (following destruction frame) in region of interest in the anterior left ventricular myocardial wall of WT (129SvEv),  $Kv\beta1.1^{-/-}$ , and  $Kv\beta2^{-/-}$  mice. Data were fit with exponential function (see inset). (C,D) Summary of MBF as a function of cardiac workload (double product; heart rate x mean arterial pressure) in  $Kv\beta1.1^{-/-}$  (C) and  $Kv\beta2^{-/-}$  (D) versus strain-matched wild type (WT) control mice. Data were fit with a simple linear regression model with slopes: WT ( $0.00192 \pm 0.00031$ ),  $Kv\beta1.1^{-/-}$  ( $0.00279 \pm 0.00016$ ); n = 6–8 mice; WT ( $0.00241 \pm 0.00014$ ),  $Kv\beta2^{-/-}$  ( $0.00162 \pm 0.00022$ ); n = 4–8 mice, \*P<0.05, slope of  $Kv\beta2^{-/-}$  vs. WT.



**Figure 3: Ablation of Kvβ2 attenuates hypoxia-induced coronary vasodilation.** (A) Summarized bath O<sub>2</sub> (%) measured in normoxic and hypoxic conditions (perfusate aerated with 5% CO<sub>2</sub>, balance N<sub>2</sub>, + 1 mM Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub>); data are pooled from measurements obtained with wild type (129SvEv) and Kvβ2<sup>-/-</sup> coronary arteries. n = 7–9, \*\*\*P<0.001 (Mann Whitney U). (B) Representative arterial diameter recordings in isolated precontracted (100 nM U46619) coronary arteries from wild type (WT; 129SvEv) and Kvβ2<sup>-/-</sup> mice in normoxic and hypoxic conditions. Ca<sup>2+</sup>-free perfusate containing nifedipine (nifed; 1 μM) and forskolin (fsk; 0.5 μM) was introduced at the end of the


experiment to induce maximum dilation. (C) Scatter-plot and mean  $\pm$  SEM showing percent decrease in diameter recorded under normoxic (- hypoxia) and hypoxic (+ hypoxia) conditions for arteries from WT and  $Kv\beta 2^{-/-}$  mice. Normoxic and hypoxic conditions were both applied in continuous presence of U46619, see above (B). n = 5 arteries, 3–4 mice \*P<0.05, ns: P 0.05 (one-way ANOVA, Tukey). (D) Scatter-plot and mean  $\pm$  SEM showing hypoxia-induced dilation (%) for arteries from WT and  $Kv\beta 2^{-/-}$  mice. \*\*P<0.01 (Mann-Whitney U test).



**Figure 4: L-lactate enhances  $I_{Kv}$  in coronary arterial myocytes and promotes coronary vasodilation via  $Kv\beta 2$ .**

(A, B) Representative outward  $K^+$  current recordings normalized to cell capacitance (pA/pF) in response to step-wise (10 mV) depolarization to +50 mV from a holding potential of -70 mV in isolated coronary arterial myocytes. Currents were recorded before and after application of 10 mM L-lactate in bath solution lacking (A) or containing (B) 500 nM psora-4. (C, D) Summary current-voltage relationships obtained in coronary arterial myocytes before and after application of 10 mM L-lactate in bath solution lacking (C)


or containing (*D*) 500 nM psora-4.  $n = 5-7$  cells from 4-7 mice. \* $P < 0.05$ , ns:  $P = 0.05$  (two-way RM ANOVA). (*E*) Summary of L-lactate-induced currents recorded in the absence and presence of 500 nM psora-4.  $n = 5-7$  cells from 4-7 mice. \* $P < 0.05$  (mixed-effects). (*F-H*) Arterial diameter traces obtained from pressurized (80 mmHg) coronary arteries isolated from wild type (WT; 129SvEv; *F,G*) and  $Kv\beta 2^{-/-}$  (*H*) mice in the absence and presence of L-lactate (5-20 mM, as indicated). Arteries were precontracted with 100 nM U46619; for WT arteries, L-lactate was applied in the absence (*top*) and presence (*bottom*) of psora-4 (500 nM). Maximum passive diameter was recorded at the end of each experiment in  $Ca^{2+}$ -free saline solution with nifedipine (nifed; 1  $\mu M$ ) and forskolin (fsk; 0.5  $\mu M$ ). (*I*) Summary plot showing L-lactate-induced dilation, expressed as a percent change from baseline diameter relative to maximum passive diameter, for arteries isolated from WT (129SvEv;  $\pm$  500 nM psora-4) and  $Kv\beta 2^{-/-}$  mice.  $n = 4$  arteries from 4 mice for each. \* $P < 0.001$ ; ns:  $P = 0.05$ , lactate vs. baseline (Friedman).



**Figure 5: Kvβ2 controls redox-dependent vasoreactivity in resistance mesenteric arteries.** (A) Representative fluorescence images showing PLA-associated fluorescent punctae (red) in wild type coronary and mesenteric arterial myocytes. Cells were labelled for Kv1.5 alone, or co-labelled for Kv1.5 and Kv1.2, Kv1.5 and Kvβ1.1, Kv1.5 and Kvβ2, or Kvβ1.1 and Kvβ2 proteins. DAPI nuclear stain is shown for each condition (blue). Scale bars represent 5  $\mu\text{m}$ . (B) Summary of PLA-associated punctate sites normalized to total cell footprint area for conditions and groups as in D. P values are shown for coronary versus mesenteric arteries (Mann Whitney U). (C,D) Arterial diameter traces obtained from pressurized (80 mmHg)



mesenteric arteries isolated from wild type (*C*; 129SvEv) and  $Kv\beta 2^{-/-}$  (*D*) mice in the absence and presence of L-lactate (5–20 mM, as indicated). Arteries were precontracted with 100 nM U46619 and L-lactate was applied in the absence (*top*) and presence (*bottom*) of the selective Kv1 channel inhibitor psora-4 (500 nM). Maximum passive diameters were recorded at the end of each experiment in  $Ca^{2+}$ -free saline solution with nifedipine (nifed; 1  $\mu$ M) and forskolin (fsk; 0.5  $\mu$ M). (**E**) Summary plot of L-lactate-induced dilation, expressed as the percent change from baseline diameter relative to maximum passive diameter, for arteries isolated from WT (129SvEv;  $\pm$  psora-4) and  $Kv\beta 2^{-/-}$  mice. n = 5 arteries from 4–5 mice for each. \* $P < 0.05$ ; ns:  $P \geq 0.05$ , lactate vs. baseline (Friedman).



**Figure 6: Increasing the ratio of Kv $\beta$ 1.1:Kv $\beta$ 2 subunits in smooth muscle inhibits L-lactate-induced vasodilation and suppresses myocardial blood flow.**

(A) Schematic diagram describing the SM22 $\alpha$ -rtTA:TRE- $\beta$ 1 model. Double transgenic animals (+dox) results in activation of the reverse tetracycline trans-activator (rtTA) in smooth muscle cells, and drives expression of Kv $\beta$ 1.1. (B) Western blots showing immunoreactive bands for Kv $\beta$ 1 in whole mesenteric artery and brain lysates from SM22 $\alpha$ -rtTA (single transgenic control) and SM22 $\alpha$ -rtTA:TRE- $\beta$ 1 (double transgenic) mice after doxycycline treatment. Ponceau-stained membrane (mol. Wt.: ~30–55 kDa) is shown as

an internal control for total loaded protein. **(C)** Summarized relative densities of Kv $\beta$ 1.1-associated immunoreactive bands in mesenteric arteries and brains of SM22 $\alpha$ -rtTA: TRE- $\beta$ 1 relative to SM22 $\alpha$ -rtTA. n = 3 each. \*P<0.05, ns: P 0.05 (one sample t test). **(D)** Representative fluorescence images showing PLA-associated fluorescent punctae (red) in coronary arterial myocytes isolated from SM22 $\alpha$ -rtTA and SM22 $\alpha$ -rtTA: TRE- $\beta$ 1 mice. Cells were labelled for Kv1.5 alone, or co-labelled for Kv1.5 and Kv $\beta$ 1, or Kv1.5 and Kv $\beta$ 2 proteins. DAPI nuclear stain is shown for each condition (blue). Scale bars represent 5  $\mu$ m. **(E)** Summary of PLA-associated punctate sites normalized to total cell footprint area for conditions and groups as in D. n = 6–19 cells from 2–3 mice for each; \*P<0.05, \*\*P<0.001 (Mann Whitney U). **(F)** Representative arterial diameter recordings from 100 nM U46619-precontracted mesenteric arteries isolated from SM22 $\alpha$ -rtTA and SM22 $\alpha$ -rtTA: TRE- $\beta$ 1 mice in the absence and presence of L-lactate (5–20 mM), as in Figure 5C,D. Passive dilation in the presence of Ca<sup>2+</sup>-free solution + nifedipine (1  $\mu$ M) and forskolin (fsk; 0.5  $\mu$ M) is shown for each recording. **(G)** Summary plot of L-lactate-induced dilation for arteries isolated from SM22 $\alpha$ -rtTA and SM22 $\alpha$ -rtTA: TRE- $\beta$ 1 mice. n = 6–10 arteries from 5–6 mice; \*P<0.05; ns: P 0.05, lactate vs. baseline (Friedman). **(H)** Summary relationships between myocardial blood flow (MBF) and cardiac workload (double product; heart rate x mean arterial pressure) in SM22 $\alpha$ -rtTA: TRE- $\beta$ 1 vs. SM22 $\alpha$ -rtTA control mice. n = 5 each; \*\*\*P<0.001 (linear regression).